Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma

被引：23
|
作者：
Girgis, Suzette [1 ,3 ]
Lin, Shun Xin Wang [1 ]
Pillarisetti, Kodandaram [1 ]
Verona, Raluca [1 ]
Vieyra, Diego [1 ]
Casneuf, Tineke [2 ]
Fink, Damien [1 ]
Miao, Xin [1 ]
Chen, Yang [1 ]
Stephenson, Tara [1 ]
Banerjee, Arnob [1 ]
Hilder, Brandi W. [1 ]
Russell, Jeffery [1 ]
Infante, Jeffrey [1 ]
Elsayed, Yusri [1 ]
Smit, Jennifer [1 ]
Goldberg, Jenna D. [1 ]
机构：
[1] Janssen Res & Dev LLC, Spring House, PA USA
[2] Janssen Res & Dev LLC, Beerse, Belgium
[3] Janssen Res & Dev, 920 Route 202, Raritan, NJ 08869 USA
来源：
BLOOD ADVANCES | 2023年 / 7卷 / 04期
关键词：
CELL MATURATION ANTIGEN; BONE-MARROW; SURVIVAL;
D O I：
10.1182/bloodadvances.2022007625
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：644 / 648
页数：5
相关论文
共 50 条
  • [21] Treatment preferences of patients with relapsed and refractory multiple myeloma: a qualitative study
    Parsons, Janet
    Greenspan, Nicole
    Baker, Natalie
    McKillop, Chris
    Hicks, Lisa
    Chan, Olivia
    BMC CANCER, 2019, 19 (1)
  • [22] A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
    Mei, Heng
    Li, Chenggong
    Jiang, Huiwen
    Zhao, Xinying
    Huang, Zhiping
    Jin, Dan
    Guo, Tao
    Kou, Haiming
    Liu, Lin
    Tang, Lu
    Yin, Ping
    Wang, Zhihui
    Ai, Lisha
    Ke, Sha
    Xia, Yimeng
    Deng, Jun
    Chen, Lei
    Cai, Li
    Sun, Chunyan
    Xia, Linghui
    Hua, Gaoquan
    Hu, Yu
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
  • [23] Salvage therapy with bortezomib and dexamethasone in elderly patients with relapsed/refractory multiple myeloma
    Castelli, Roberto
    Pantaleo, Giuseppe
    Gallipoli, Paolo
    Gidaro, Antonio
    Arquati, Massimo
    Wu, Maddalena A.
    Deliliers, Giorgio Lambertenghi
    ANTI-CANCER DRUGS, 2015, 26 (10) : 1078 - 1082
  • [24] Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients
    Visram, A.
    Soof, C.
    Rajkumar, S. V.
    Kumar, S. K.
    Bujarski, S.
    Spektor, T. M.
    Kyle, R. A.
    Berenson, J. R.
    Dispenzieri, A.
    BLOOD CANCER JOURNAL, 2021, 11 (06)
  • [25] Promising therapeutic approaches for relapsed/refractory multiple myeloma
    Ni, Beiwen
    Hou, Jian
    HEMATOLOGY, 2022, 27 (01) : 343 - 352
  • [26] Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma
    Sheikh, Semira
    Lebel, Eyal
    Trudel, Suzanne
    FUTURE ONCOLOGY, 2020, 16 (34) : 2783 - 2798
  • [27] Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
    Wang, Ying
    Li, Chunrui
    Xia, Jieyun
    Li, Ping
    Cao, Jiang
    Pan, Bin
    Tan, Xu
    Li, Hujun
    Qi, Kunming
    Wang, Xiangmin
    Shi, Ming
    Jing, Guangjun
    Yan, Zhiling
    Cheng, Hai
    Zhu, Feng
    Sun, Haiying
    Sang, Wei
    Li, Depeng
    Zhang, Xi
    Li, Zhenyu
    Zheng, Junnian
    Liang, Aibin
    Zhou, Jianfeng
    Xu, Kailin
    BLOOD ADVANCES, 2021, 5 (23) : 5290 - 5299
  • [28] Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma
    Baljevic, Muhamed
    Zaman, Shadia
    Baladandayuthapani, Veerabhadran
    Lin, Yan Heather
    de Partovi, Claudia Morales
    Berkova, Zuzana
    Amini, Behrang
    Thomas, Sheeba K.
    Shah, Jatin J.
    Weber, Donna M.
    Fu, Min
    Cleeland, Charles S.
    Wang, Xin Shelley
    Stellrecht, Christine M.
    Davis, Richard E.
    Gandhi, Varsha
    Orlowski, Robert Z.
    ANNALS OF HEMATOLOGY, 2017, 96 (06) : 977 - 985
  • [29] The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma
    Rejeski, Kai
    Hansen, Doris K.
    Bansal, Radhika
    Sesques, Pierre
    Ailawadhi, Sikander
    Logue, Jennifer M.
    Braeunlein, Eva
    dos Santos, David M. Cordas M.
    Freeman, Ciara L.
    Alsina, Melissa
    Theurich, Sebastian
    Wang, Yucai
    Krackhardt, Angela M.
    Locke, Frederick L.
    Bachy, Emmanuel
    Jain, Michael D.
    Lin, Yi
    Subklewe, Marion
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
  • [30] Efficacy and safety of chimeric antigen receptor T cells targeting BCMA and GPRC5D in relapsed or refractory multiple myeloma
    Yang, Xu
    Wang, Feiqing
    Yuan, Xiaoshuang
    Yang, Bo
    Chen, Juan
    Cheng, Jinyang
    Liu, Guangyang
    Tang, Dongxin
    Xu, Xiao
    Wang, Sanbin
    He, Zhixu
    Liu, Yang
    Li, Yanju
    FRONTIERS IN IMMUNOLOGY, 2024, 15
12345